09/29/2026
What changed in the FDA’s updated substantial evidence guidance, and what could it mean for rare disease therapy development?
The FDA recently updated an important guidance document commonly referred to as the “substantial evidence guidance.”
In our latest blog, we explore the background of the substantial evidence standard, why it matters for rare disease therapy development, and what the RARE Foundation recommended in our comments to the FDA on the draft updates.
Read blog post here: https://www.rareadvocates.org/news/the-updated-substantial-evidence-guidance/